Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE® Anti-Infectives

SYDNEY, Australia, Nov. 23, 2020 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing new classes of synthetic anti-infectives, is pleased to announce the Japan Patent Office (JPO) has granted Patent Family 3 titled “Anti-virus Agent and Method for Treatment of Viral Infection”, furthering marketing and manufacturing monopolies to February 2037.

“Recce’s intellectual property portfolio continues to grow in-line with our business strategy and the unprecedented global infectious disease crisis before us,” said Chief Executive Officer, James Graham. “At now 31 granted patents across three wholly-owned patent families, our market-monopolies reinforce our unique opportunity among a significant-range of both bacterial and viral pathogens.”

Japan Patent Office granted claims relate to RECCE^® 327 (R327) and new anti-viral formulation RECCE^® 529 (R529), most notably:

• Composition/method of manufacture of RECCE^® anti-infectives
• Use of R327 or R529 for the treatment of viruses having a lipid envelope or coat, examples being SARS-CoV-2 and coronaviruses, influenza viruses, HIV, hepatitis, Ross River and Herpes viruses
• Administration of R327 or R529 by oral, injection, inhalation and transdermal dose applications

Japan is the second largest pharmaceutical market in the world¹ with the unmet medical need from infections caused by lipid enveloped or coated viruses representing millions of potential patients Japan country alone. Patent Family 3 applications in other major pharmaceutical markets around the world are in their advanced stages of independent patent reviews.

__________________________________

¹ https://www.worldatlas.com/articles/countries-with-the-biggest-global-pharmaceutical-markets-in-the-world.html

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialization of New Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.

Recce’s anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE^® 327 and RECCE^® 435, and RECCE^® 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.

Patented lead candidate RECCE^® 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. Recce’s new antibiotic compound, RECCE^® 435, has been formulated for oral use.

The FDA has awarded RECCE^® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.

Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of RECCE^® technologies targeting synergistic, unmet medical needs.

Corporate Contact
James Graham
Recce Pharmaceuticals Ltd
+61 (02) 8075 4585
James.graham@recce.com.au

Media and Investor Relations (AU)
Andrew Geddes
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au

Media and Investor Relations (USA)
Meredith Sosulski, Ph.D.
LifeSci Communications
+1 929 469 3851
msosulski@lifescicomms.com